Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADOIF
Adocia
C$8.87
C$8.87
C$8.87
▼
C$11.24
N/AN/A2,000 shsN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.00
$0.00
▼
$0.01
N/A11.9969 shsN/A
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
C$15.51
C$13.40
C$7.70
▼
C$17.25
N/AN/A2,082 shsN/A
TRSBF
3SBio
$2.12
$2.15
$2.00
▼
$4.74
N/AN/A2,351 shsN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADOIF
Adocia
0.00%0.00%0.00%0.00%0.00%
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%0.00%0.00%-99.00%
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
0.00%0.00%+15.23%+74.76%+41.39%
TRSBF
3SBio
0.00%0.00%-1.48%-16.94%-45.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADOIF
Adocia
C$8.87
C$8.87
C$8.87
▼
C$11.24
N/AN/A2,000 shsN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.00
$0.00
▼
$0.01
N/A11.9969 shsN/A
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
C$15.51
C$13.40
C$7.70
▼
C$17.25
N/AN/A2,082 shsN/A
TRSBF
3SBio
$2.12
$2.15
$2.00
▼
$4.74
N/AN/A2,351 shsN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADOIF
Adocia
0.00%0.00%0.00%0.00%0.00%
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%0.00%0.00%-99.00%
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
0.00%0.00%+15.23%+74.76%+41.39%
TRSBF
3SBio
0.00%0.00%-1.48%-16.94%-45.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADOIF
Adocia
0.00
N/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00
N/AN/AN/A
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
0.00
N/AN/AN/A
TRSBF
3SBio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADOIF
Adocia
N/AN/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/AN/A
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADOIF
Adocia
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/A-$0.84N/AN/AN/AN/AN/AN/AN/A
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/A-C$0.01N/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ADOIF
Adocia
N/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/A
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ADOIF
Adocia
N/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/A
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
1.74%
TRSBF
3SBio
N/A

Insider Ownership

CompanyInsider Ownership
ADOIF
Adocia
N/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
28.20%
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/A
TRSBF
3SBio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ADOIF
Adocia
97N/AN/ANot Optionable
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
211.63 million8.35 millionNot Optionable
Neuren Pharmaceuticals Limited stock logo
NURPF
Neuren Pharmaceuticals
N/AN/AN/ANot Optionable
TRSBF
3SBio
5,411N/AN/ANot Optionable

Recent News About These Companies

3SBio Board to Review 2026 Interim Results and Consider Dividend
August 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-board-to-review-2026-interim-results-and-consider-dividend?utm_source=marketbeat.com&utm_medium=referral
3SBio Sets June 2026 AGM to Approve Dividend, New Auditor and Share Issue Mandate
June 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-sets-june-2026-agm-to-approve-dividend-new-auditor-and-share-issue-mandate?utm_source=marketbeat.com&utm_medium=referral
3SBio Calls Extraordinary Meeting to Approve Mandi Spin-Off Dividend
April 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-calls-extraordinary-meeting-to-approve-mandi-spin-off-dividend?utm_source=marketbeat.com&utm_medium=referral
3SBio Proposes HKD 0.25 Final Dividend for 2025 Financial Year
March 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-proposes-hkd-0-25-final-dividend-for-2025-financial-year?utm_source=marketbeat.com&utm_medium=referral
Chinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- Update
May 20, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/chinese-biotech-stocks-surge-after-3sbio-s-6-billion-licensing-deal-with-pfizer-update-22768f03
Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer
May 20, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/biotech-company-3sbio-s-shares-surge-after-6-billion-licensing-deal-with-pfizer-6bf7cbed
Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion
May 20, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/pfizer-licenses-3sbio-cancer-drug-for-record-12-billion/ar-AA1F5ZDf
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
July 28, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cosmo-and-3sbio-announce-signing-of-license-agreement-for-winlevi-174-in-china-1031624145
3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development
August 26, 2021  |  finance.yahoo.comhttps://finance.yahoo.com/news/3sbio-announces-2021-interim-results-140900893.html?.tsrc=rss

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adocia OTCMKTS:ADOIF

C$8.87 0.00 (0.00%)
As of 05/12/2023

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Adhera Therapeutics stock logo

Adhera Therapeutics OTCMKTS:ATRX

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Neuren Pharmaceuticals stock logo

Neuren Pharmaceuticals OTCMKTS:NURPF

C$15.51 0.00 (0.00%)
As of 08/25/2026

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

3SBio OTCMKTS:TRSBF

$2.12 0.00 (0.00%)
As of 08/25/2026

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas